Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 921864, 8 pages
http://dx.doi.org/10.1155/2014/921864
Research Article

CD8+ TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors

1Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, Barão Geraldo, 13083-887 Campinas, SP, Brazil
2Department of Biological Sciences and Health, State University of Roraima (UERR), Rua Sete de Setembro 231, 69306-530 Boa Vista, RR, Brazil
3Department of Pathology, AC Camargo Hospital, Antonio Prudente Foundation, 211 Professor Antonio Prudente Street, 01509-010 São Paulo, SP, Brazil
4Laboratory of Investigative and Molecular Pathology, CIPED, Faculty of Medical Sciences (FCM), University of Campinas (Unicamp), 126 Tessália Vieira de Camargo Street, 13083-887 Campinas, SP, Brazil

Received 7 July 2014; Accepted 9 October 2014; Published 4 November 2014

Academic Editor: Nitya G. Chakraborty

Copyright © 2014 Mariana Bonjiorno Martins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y.-T. Chen, and L. J. Old, “Cancer/testis antigens, gametogenesis and cancer,” Nature Reviews Cancer, vol. 5, no. 8, pp. 615–625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. W. Zendman, D. J. Ruiter, and G. N. P. van Muijen, “Cancer/testis-associated genes: identification, expression profile, and putative function,” Journal of Cellular Physiology, vol. 194, no. 3, pp. 272–288, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. L. J. Old, “Cancer/Testis (CT) antigens—a new link between gametogenesis and cancer,” Cancer Immunity, vol. 1, pp. 1–7, 2001. View at Google Scholar · View at Scopus
  4. B. Gaugler, B. Van Den Eynde, P. Van Der Bruggen et al., “Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes,” Journal of Experimental Medicine, vol. 179, no. 3, pp. 921–930, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Yang, S. O'Herrin, J. Wu et al., “Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo,” Journal of Investigative Dermatology, vol. 127, no. 2, pp. 267–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Yang, J. Wu, N. Maddodi, Y. Ma, V. Setaluri, and B. J. Longley, “Epigenetic control of MAGE gene expression by the KIT tyrosine kinase,” Journal of Investigative Dermatology, vol. 127, no. 9, pp. 2123–2128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. I. Miranda, “MAGE, biological functions and potential clinical applications,” Leukemia Research, vol. 34, no. 9, pp. 1121–1122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. de Plaen, K. Arden, C. Traversari et al., “Structure, chromosomal localization, and expression of 12 genes of the MAGE family,” Immunogenetics, vol. 40, no. 5, pp. 360–369, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Martinez, I. Olarte, M. A. Mergold et al., “mRNA expression of MAGE-A3 gene in leukemia cells,” Leukemia Research, vol. 31, no. 1, pp. 33–37, 2007. View at Publisher · View at Google Scholar
  10. C. Gérard, N. Baudson, T. Ory, and J. Louahed, “Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses,” PLoS ONE, vol. 9, no. 5, Article ID e94883, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. V. G. Brichard and Q. Godechal, “MAGE-A3-specific anticancer immunotherapy in the clinical practice,” OncoImmunology, vol. 2, no. 10, Article ID e25995, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D. S. Cooper, and G. M. Doherty, “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar
  13. P. W. Rosário, L. S. Ward, G. A. Carvalho et al., “Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus,” Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 57, no. 4, pp. 240–264, 2013. View at Google Scholar
  14. E. C. Morari, J. R. Silva, A. C. T. Guilhen et al., “Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome,” Endocrine Pathology, vol. 21, no. 4, pp. 242–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. L. Cunha, E. C. Morari, A. C. T. Guihen et al., “Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma,” Clinical Endocrinology, vol. 77, no. 6, pp. 918–925, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. L. L. Cunha, E. C. Morari, A. C. T. Guihen et al., “Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer,” Endocrine-Related Cancer, vol. 19, no. 3, pp. L31–L36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. O. L. Caballero and Y.-T. Chen, “Cancer/testis (CT) antigens: Potential targets for immunotherapy,” Cancer Science, vol. 100, no. 11, pp. 2014–2021, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Milkovic, B. Sarcevic, and E. Glavan, “Expression of MAGE tumor-associated antigen in thyroid carcinomas,” Endocrine Pathology, vol. 17, no. 1, pp. 45–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Cheng, W. Liu, M. Mercado, S. Ezzat, and S. L. Asa, “Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 455–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Maio, S. Coral, L. Sigalotti et al., “Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 2, pp. 748–754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Ruschenburg, A. Kubitz, T. Schlott, M. Korabiowska, and M. Droese, “MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter,” International Journal of Molecular Medicine, vol. 4, no. 4, pp. 445–448, 1999. View at Google Scholar · View at Scopus
  22. T. Kondo, X. Zhu, S. L. Asa, and S. Ezzat, “The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer,” Clinical Cancer Research, vol. 13, no. 16, pp. 4713–4720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Liu, S. Cheng, S. L. Asa, and S. Ezzat, “The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis,” Cancer Research, vol. 68, no. 19, pp. 8104–8112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Cuppens and J. Vansteenkiste, “Vaccination therapy for non-small-cell lung cancer,” Current Opinion in Oncology, vol. 26, no. 2, pp. 165–170, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. W. H. Kruit, S. Suciu, B. Dreno et al., “Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2413–2420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Escudier, “Emerging immunotherapies for renal cell carcinoma,” Annals of Oncology, vol. 23, no. 8, Article ID mds261, pp. viii35–viii40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Oshita, M. Takikawa, A. Kume et al., “Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial,” Oncology Reports, vol. 28, no. 4, pp. 1131–1138, 2012. View at Publisher · View at Google Scholar · View at Scopus